The FDA announced on January 12 that they propose delaying “indefinitely” the publication of final rules on regulations describing the evidence that may be considered in determining a medical product’s intended uses. (21 CFR 201.128—drugs and 21 CFR 801.4—devices.)

On December 22, 2017, after vigorous public hearings and comments, New Jersey adopted new rules limiting pharmaceutical manufacturer payments to prescribers to $10,000 per year and imposing a $15 meal cap. The law goes into effect January 15, 2018.